Anti-Tumor Effect and Drug Delivery of Biomimetic Exosomes Nanoplatform Loading with Paclitaxel (PTX) for Treating Lung Adenocarcinoma

Author:

Liu Xi1,Dai Weibo2,Xu Wenhua3,Chen Yao1

Affiliation:

1. Department of Pharmacy, Zhongshan Torch Development Zone People’s Hospital, Zhongshan 528437, China

2. Department of Pharmacy, Zhongshan Hospital of Traditional Chinese Medicine, Zhongshan 528401, China

3. Prevention and Treatment Center, Shenzhen Hospital of Integrated Traditional Chinese and Western Medicine, Guangzhou University of Chinese Medicine, Shenzhen 518027, China

Abstract

This study constructed an exosome (Exo) nanomedicine with the ability to actively penetrate into lung tumor tissue, in order to improve the anti-tumor effect of paclitaxel (PTX). For reaching this goal A549 lung adenocarcinoma cells were employed. The exosomes were collected by gradient centrifugation, and the Exo/PTX was prepared after targeted modification. Then the in vitro properties and in vivo tumor inhibitory effects of Exo/PTX were then characterized and evaluated. to conduct in vitro and in vivo study. The prepared Exo/PTX had a particle size of about 100 nm, and had a saucer-like double-layer membrane structure, which had a high encapsulation efficiency and drug loading. in vitro studies have shown that Exo/PTX can be largely taken up by lung cancer cells, thereby enhancing the drug’s effects on promoting apoptosis. The results of in vivo experiments showed that Exo/PTX can effectively inhibit the growth of tumor tissue. The results of this study showed that using exosome for drug delivery of PTX can increase the efficacy and decrease the drug toxicity and side effects.

Publisher

American Scientific Publishers

Subject

General Medicine

Reference29 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA: A Cancer Journal for Clinicians,2018

2. International Association for the Study of Lung Cancer International Staging Committee, The IASLC lung cancer staging project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours;Goldstraw;Journal of Thoracic Oncology,2007

3. Treatment for small cell lung cancer, where are we now?—A review;Alvarado-Luna;Translational Lung Cancer Research,2016

4. Identifying an optimum treatment strategy for patients with advanced nonsmall cell lung cancer;Grossi;Critical Reviews in Oncology/Hematology,2008

5. Combined modality treatments in early non-small cell lung cancer;Harper;Lung Cancer,2002

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3